Argos Therapeutics Inc (ARGS) Price Target Lowered to $1.20 at FBR & Co

Modesto Morganelli
Aprile 21, 2017

The Relative Strength Index (RSI), developed by J. Welles Wilder, is a momentum oscillator that calculates the speed and change of price movements. The RSI oscillates between zero and 100.

02/22/2017 - Argos Therapeutics Inc was downgraded to "market perform" by analysts at FBR Capital Markets. (ARGS) is at 32.91. They now have a Dollars 11 price target on the stock. It represents a security's price that, if achieved, results in a trader recognizing the best possible outcome for his investment. For the past 5 years, the company's revenue has grown -10.1%, while the company's earnings per share has grown 0%. Analyst's consensus target price is measured at $1.6000 for twelve month. Different analysts and financial institutions use various valuation methods and consider different economic forces when deciding on a price target.

Yet another important factor while evaluating a good buy/sell decision for Argos Therapeutics, Inc.

Earnings per share (EPS) is the portion of a company's profit allocated to each outstanding share of common stock. Earnings per share serves as an indicator of a company's profitability. Consensus earnings estimates are far from ideal, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock. The average analysts gave this company a mean recommendation of 2.20.

Analysts have placed a $1.6 price target on Argos Therapeutics, Inc., suggesting a 166.67% gain from recent close. ARGS has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 0.47 and Price to Free Cash Flow (P/FCF) value of 0. Wasatch Advisors Inc. raised its position in shares of Argos Therapeutics by 35.2% in the third quarter. The high and low revenue estimates for the current quarter are $150000 and $100000, respectively. The Portland, Oregon-based Company's quarterly revenues surged 32% y-o-y and reported net income for the period. Look at the direction of the moving average to get a basic idea of which way the price is moving. Angled up and price is moving up (or was recently) overall, angled down and price is moving down overall, moving sideways and the price is likely in a range. Company's distance from 20 day simple moving average is -21.46% and distance from 50-Day simple moving average is -78.15%. Stifel Nicolaus lowered shares of Argos Therapeutics from a buy rating to a hold rating and set a $1.40 price objective for the a research note on Wednesday, February 22nd. (ARGS) in which Roth Capital Maintains Argos Therapeutics, Inc.

JMP Securities Downgrade its coverage for Argos Therapeutics, Inc. (ARGS) in a note sent to investors on 22-Feb-17. The research firm Downgrade the stock to Mkt Perform. FBR & Co now has a mkt perform rating on the biopharmaceutical company's stock. The stock established a positive trend of 75.95% in last week and indicated fall of -29.41% in previous month. EPS ratio determined by looking at last 12 month figures is -1.87.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE